Roopa Industries

Which are the latest news on Roopa Industries?

Why is Roopa Industries Ltd falling/rising?

As of 05-Sep, Roopa Industries Ltd's stock price is at 49.45, down 0.6%. This decline is due to erratic trading patterns, reduced investor participation, and a year-over-year drop in stock value, despite a year-to-date gain.

As of 05-Sep, Roopa Industries Ltd's stock price is currently at 49.45, reflecting a decrease of 0.3, or 0.6%. This decline can be attributed to several factors. Firstly, the stock has shown erratic trading patterns, having not traded on 2 out of the last 20 days, which may indicate a lack of consistent investor interest. Additionally, there has been a notable drop in investor participation, with delivery volume on September 1 falling by 49.06% compared to the 5-day average. <BR><BR>While the stock has performed well over the year-to-date with a gain of 12.28% compared to a decline of 10.21% in the Sensex, it has experienced a year-over-year decline of 8.15%, which could be affecting investor sentiment. Furthermore, the stock's current price is higher than its 20-day, 50-day, and 200-day moving averages, but lower than its 5-day and 100-day moving averages, suggesting mixed signals regarding its short-term performance. Overall, these factors contribute to the stock's current downward movement.

Who are in the management team of Roopa Industries?

The management team of Roopa Industries consists of T G Raghavendra (Chairman & Managing Director), V J Sarma (Whole-time Director), and three Non-Executive & Independent Directors: O Mohan Rao, A Satyanarayana Murthy, and Karunasree.

The management team of Roopa Industries includes the following individuals:<BR><BR>1. T G Raghavendra - Chairman & Managing Director<BR>2. V J Sarma - Whole-time Director<BR>3. O Mohan Rao - Non-Executive & Independent Director<BR>4. A Satyanarayana Murthy - Non-Executive & Independent Director<BR>5. Karunasree - Non-Executive & Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Roopa Industries do?

Roopa Industries Ltd manufactures bulk drugs and drug intermediates in the pharmaceuticals sector and has a market cap of INR 39 Cr. As of June 2026, it reported net sales of 33 Cr and a net profit of 0 Cr.

Overview: <BR>Roopa Industries Ltd is engaged in the manufacturing of bulk drugs and drug intermediates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>History: <BR>Roopa Industries Limited was incorporated in 1985 as "Roopa Granites Private Limited," changed its name to "Roopa Granites Limited" in 1992, and further rebranded to M/s. Roopa Industries in 1994. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 33 Cr (Quarterly Results - Jun 2026) <BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>- Market Cap: INR 39 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 9.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 1.68 <BR>- Return on Equity: 23.98% <BR>- Price to Book: 2.15 <BR><BR>Contact Details: <BR>Address: 17/745 Alur Road, Kurnool District ADONI Andhra Pradesh : 518301 <BR>Fax: 91-40-23310379 <BR>Email: info@roopaindustries.com <BR>Website: http://www.roopaindustries.com

Who are the peers of the Roopa Industries?

Peers of Roopa Industries include Vasundhara Rasy., Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, Vista Pharma, and Chandra Bhagat. Parmax Pharma shows the highest 1-year return at 273.20%, while Roopa Industries has a return of -15.70%.

Peers: The peers of Roopa Industries are Vasundhara Rasy., Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, Vista Pharma., and Chandra Bhagat.<BR><BR>Quality Snapshot: Excellent management risk is observed at Parmax Pharma, while Average management risk is found at Vasundhara Rasy. and Rajnish Wellness. Below Average management risk is present at Kabra Drugs, ANG Lifesciences, Vivo Bio Tech, Murae Organisor, Vista Pharma., Chandra Bhagat, and the rest. Growth is Excellent at Roopa Industries, while Average growth is seen at Vasundhara Rasy. and the rest. Below Average growth is noted at Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, Vista Pharma., and Chandra Bhagat. Capital Structure is Good at Vasundhara Rasy., while Below Average capital structure is found at Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, Vista Pharma., Chandra Bhagat, and Roopa Industries.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parmax Pharma at 273.20%, while the lowest is Murae Organisor at -72.86%. Roopa Industries has a 1-year return of -15.70%, which is higher than Murae Organisor but lower than Parmax Pharma. Additionally, the six-month return is negative for Kabra Drugs, Rajnish Wellness, Vivo Bio Tech, Murae Organisor, and Vista Pharma.

How big is Roopa Industries?

As of 31st August, Roopa Industries Ltd has a market capitalization of 39.00 Cr, with recent Net Sales of 125.74 Cr and a Net Profit of 0.13 Cr. The company reported Shareholder's Funds of 17.49 Cr and Total Assets of 76.46 Cr for the annual period ending in March 2025.

As of 31st August, Roopa Industries Ltd has a market capitalization of 39.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Roopa Industries reported Net Sales of 125.74 Cr and a Net Profit of 0.13 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds of 17.49 Cr and Total Assets amounting to 76.46 Cr.

Should I buy, sell or hold Roopa Industries Ltd?

Are Roopa Industries Ltd latest results good or bad?

Roopa Industries Ltd's latest results show improved operational efficiency with a highest operating margin of 10.19%, but the company reported a net loss of ₹1.43 crores, contrasting with a profit in the previous quarter, raising concerns about its growth sustainability. While there are operational gains, the decline in revenue and net loss indicate challenges ahead for investors.

Roopa Industries Ltd's latest results for Q4 FY26 present a mixed picture. On one hand, the company achieved its highest operating margin in eight quarters at 10.19%, indicating improved operational efficiency. However, this positive operational performance was overshadowed by a significant net loss of ₹1.43 crores, a stark contrast to the profit of ₹0.77 crores reported in the previous quarter (Q3 FY26).<BR><BR>Revenue for the quarter was ₹30.14 crores, which reflects a 10.14% decline compared to the previous quarter but shows a slight year-on-year increase of 1.04%. The negative net profit and declining revenue raise concerns about the sustainability of the company's growth, especially given the high leverage ratios and working capital pressures it faces.<BR><BR>Overall, while Roopa Industries has demonstrated operational improvements, the recent loss at the net profit level suggests challenges that investors should carefully consider. The company's ability to maintain these operational gains while returning to profitability will be crucial moving forward.

When is the next results date for Roopa Industries Ltd?

The next results date for Roopa Industries Ltd is 30 May 2026.

The next results date for Roopa Industries Ltd is scheduled for 30 May 2026.

How has been the historical performance of Roopa Industries?

Roopa Industries has shown significant growth in net sales, increasing from 26.58 Cr in Mar'21 to 120.69 Cr in Mar'25, with profits also rising, despite a sharp increase in raw material costs. Operating profit reached 6.41 Cr in Mar'25, and profit after tax rose to 2.03 Cr, while total assets and liabilities grew to 76.46 Cr each.

Answer:<BR>The historical performance of Roopa Industries shows significant growth in net sales and profit over the years.<BR><BR>Breakdown:<BR>Roopa Industries has demonstrated a strong upward trend in net sales, increasing from 26.58 Cr in Mar'21 to 120.69 Cr in Mar'25, with a notable jump from 70.43 Cr in Mar'24. The total operating income followed a similar trajectory, reaching 120.69 Cr in Mar'25, up from 70.43 Cr in the previous year. However, raw material costs surged to 114.42 Cr in Mar'25, reflecting a substantial increase from 47.06 Cr in Mar'24. Despite this, the operating profit (PBDIT) rose to 6.41 Cr in Mar'25, compared to 5.68 Cr in Mar'24, indicating improved operational efficiency. Profit before tax also increased to 2.72 Cr in Mar'25 from 2.17 Cr in Mar'24, leading to a profit after tax of 2.03 Cr in Mar'25, up from 1.52 Cr in the prior year. The company's total assets grew to 76.46 Cr in Mar'25, while total liabilities also increased to 76.46 Cr, reflecting a balanced growth. The cash flow from operating activities showed a decline to -6.00 Cr in Mar'25, contrasting with a positive cash flow of 2.00 Cr in Mar'24, but the overall cash position improved with closing cash and cash equivalents rising to 3.00 Cr in Mar'25 from 2.00 Cr in Mar'24.

Is Roopa Industries overvalued or undervalued?

As of November 10, 2025, Roopa Industries is considered undervalued with a favorable PE Ratio of 18.65 and strong growth potential, making it a compelling investment opportunity compared to its peers, despite recent stock performance lagging behind the Sensex.

As of 10 November 2025, Roopa Industries has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE Ratio of 18.65, an EV to EBITDA of 14.98, and a PEG Ratio of 0.75, indicating strong potential for growth relative to its price.<BR><BR>In comparison to peers, Roopa Industries shows a more favorable valuation than Sun Pharma, which has a PE Ratio of 35.15 and is deemed expensive, as well as Divi's Lab, which is classified as very expensive with a PE Ratio of 71.55. Despite recent stock performance lagging behind the Sensex, particularly with a year-to-date return of -33.75% compared to the Sensex's 6.91%, the overall valuation metrics suggest that Roopa Industries presents a compelling investment opportunity.

Who are the top shareholders of the Roopa Industries?

The top shareholders of Roopa Industries are Star Niochem Pvt Limited with 18.91%, followed by public shareholder Sangeetha S at 9.51%. Individual investors own 40.95%, and there is one foreign institutional investor with a 0.25% stake, with no pledged promoter holdings or mutual funds involved.

The top shareholders of Roopa Industries include Star Niochem Pvt Limited, which holds the largest stake at 18.91%. Following that, the highest public shareholder is Sangeetha S, with a holding of 9.51%. Additionally, individual investors collectively own 40.95% of the company. There is also one foreign institutional investor (FII) with a 0.25% stake. Notably, there are no pledged promoter holdings or mutual funds involved in this company.

What is the technical trend for Roopa Industries?

As of June 4, 2025, Roopa Industries shows a neutral trend with a slight bullish bias, indicated by mixed signals from the MACD and daily moving averages, while weekly indicators suggest upward momentum.

As of 4 June 2025, the technical trend for Roopa Industries has changed from mildly bearish to sideways. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both the weekly and monthly time frames, suggesting some upward momentum. However, the daily moving averages are mildly bearish, which adds a cautionary note. The KST and Dow Theory are both mildly bullish on the weekly and monthly charts, reinforcing some positive sentiment. Overall, the current stance is neutral with a slight bullish bias, driven primarily by the weekly indicators.

Has Roopa Industries declared dividend?

No Dividend History Available